Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
about
Antiangiogenic mechanisms and factors in breast cancer treatmentBevacizumab and breast cancer: current therapeutic progress and future perspectivesKi67: a time-varying biomarker of risk of breast cancer in atypical hyperplasiaKi67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.Angiogenesis - still a worthwhile target for breast cancer therapy?Antiangiogenic therapy for breast cancerBevacizumab.Targeting angiogenesis in esophagogastric adenocarcinoma.Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivoBevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index.Blood-based biomarkers for the optimization of anti-angiogenic therapiesA clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.Recent advances in anti-angiogenic therapy of cancerClinical overview of metronomic chemotherapy in breast cancer.Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.
P2860
Q26751226-1DA8CB07-D318-4DBE-BC3C-A83F006B3C2AQ33640753-587191B0-D7D4-446E-8CB1-5E1780A7EF59Q33932379-674450A1-A910-45B1-8A2B-657784395F61Q33984087-5AECC2B1-59E6-4917-B511-39EEBF417C3DQ34423550-F32296C9-F8A4-4A56-AF48-9EE99F28D971Q34989039-CAA66799-4D2C-416F-AF1B-6D69BE35114CQ35584234-A14DB00E-C15B-4140-971A-0925116494E6Q35584958-78B8AD1D-3E48-4916-B238-CB6AC2EF54ACQ35671180-780E4801-17AC-45A5-8E4D-F4CA466BAB14Q35687877-2447004D-6EE3-450E-8FE5-A8B383B598F8Q36851857-48FE78D4-568D-43D6-A394-4F23CD11F23BQ37180350-2530E283-8C1B-4A02-8A86-6C0DBBFFC64EQ37269351-C69C7646-FF71-447B-B91A-B74053532469Q37328390-6268E1DC-06F3-40D5-9D2C-411EA672C981Q37366227-0A65410B-A92E-45A8-B780-3D55E82CCF85Q37852512-1CDEB9A3-A50B-4273-80D9-9AC335B6B61FQ38560651-FFA87D69-4162-4793-8FDD-06C396FED15EQ39455513-199EB4FC-BA8D-482F-8940-35F0F50734A3Q43622985-5DF29E54-DF37-473B-909B-D04C889BCFC0Q44265169-C84EEF58-DB65-47EF-AB4E-0FAD6E947731Q48018929-065544C5-9B5F-47D2-AF3A-1913CD79FC7E
P2860
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Preoperative bevacizumab combi ...... nical and biological activity.
@en
type
label
Preoperative bevacizumab combi ...... nical and biological activity.
@en
prefLabel
Preoperative bevacizumab combi ...... nical and biological activity.
@en
P2093
P2860
P50
P356
P1476
Preoperative bevacizumab combi ...... inical and biological activity
@en
P2093
A Cardillo
A Goldhirsch
V Bagnardi
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604741
P407
P577
2008-10-21T00:00:00Z